Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06779929 · ClinicalTrials.gov registry record

Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

A clinical trial of Type 2 Diabetes, sponsored by Brigham and Women's Hospital.

Active
Registry status
70,000
Enrollment target
1
Study location

NCT06779929 is a study of Type 2 Diabetes that is active but no longer recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 70,000 participants, above the 860-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (8040% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06779929, a study of Type 2 Diabetes, is active but no longer recruiting, sponsored by Brigham and Women's Hospital.

ACTIVE NOT RECRUITING
Registry status
70,000 participants
Enrollment target
1
Study location

Study Summary

This cohort study was initiated to emulate the design of the SURPASS-CVOT trial using observational analogues of the trial design components in a study based on insurance claims data.

Conditions Studied

Type 2 Diabetes

Interventions

  • DRUG Tirzepatide
  • DRUG Semaglutide
  • DRUG Dulaglutide

Study Locations (1)

Massachusetts

  • Brigham and Women's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 70,000 participants
Start Date 2024-11-01
Est. Completion 2026-03-01

Sponsor

Brigham and Women's Hospital

937 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06779929

The ClinicalTrials.gov registry entry for NCT06779929 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 70,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 860-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (8040% higher). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 3 interventions - of which Tirzepatide is the first listed.

NCT06779929 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06779929 about?

NCT06779929 is a clinical study titled "Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes". This cohort study was initiated to emulate the design of the SURPASS-CVOT trial using observational analogues of the trial design components in a study based on insurance claims data.

What is the current status of trial NCT06779929?

This trial is currently active not recruiting. The enrollment target is 70,000 participants. The study started on 2024-11-01. Estimated completion is 2026-03-01.

What conditions does trial NCT06779929 study?

This clinical trial studies the following conditions: Type 2 Diabetes.

What interventions are being tested in trial NCT06779929?

The interventions under investigation include: Tirzepatide (DRUG), Semaglutide (DRUG), Dulaglutide (DRUG).

Who is sponsoring clinical trial NCT06779929?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06779929 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Type 2 Diabetes

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.